

Zhuhai Chen'an Pharmaceutical Co., Ltd.
Zhuhai Chen'an Pharmaceutical Co., Ltd. was established on March 19, 1999. It is a specialized pharmaceutical sales company that has emerged in the Zhuhai Special Economic Zone and is a sister company of Zhuhai Tongyuan Pharmaceuticals Co., Ltd. In recent years, the company has achieved rapid sales growth, transitioning into a medium-sized enterprise and steadily advancing towards becoming a large-scale enterprise.
The company's vision is to "deliver value, shape excellence," and its corporate spirit is to "strive for progress, envision the future." With its unique craftsmanship and pursuit of excellence, it has gained a great reputation in the Chinese pharmaceutical industry. Chen'an Pharmaceutical has a registered capital of 5 million RMB. The company has more than 150 highly skilled and responsible employees, and it works with partners in a cooperative and mutually beneficial manner. It has already established a comprehensive marketing network nationwide.
To achieve integration between pharmaceutical manufacturing and end sales, the company has entered the industry chain through self-reporting varieties, contract processing, and national general agency investments. It has formed strategic cooperative relationships with well-known domestic and foreign companies such as Fujian Haigong Fuyao Pharmaceutical Co., Ltd., Guangdong Baikang Pharmaceutical Co., Ltd., and Shanxi Pude Pharmaceutical Co., Ltd. Over the years, the company has supplied a large number of high-quality products to the pharmaceutical market, including Injection of Dimetoin, Compound Dextrose and Sodium Chloride Injection, Intramuscular Amino Acid Injection, Levofloxacin Hydrochloride Tablets, Anshen Bunao Granules, Injection of Naloxone Hydrochloride, Naloxone Hydrochloride Injection, Enoxacin Injection, and Injection of Sodium Riboflavin Phosphate.
Utilizing extensive business channels and a professional sales team, the company has established Chen'an Pharmaceutical as a renowned brand in the Chinese pharmaceutical industry. The company currently employs 150 people, including 3 licensed pharmacists, 1 pharmaceutical-related technical personnel, and 11 individuals with college degrees or above, accounting for 74% of the total workforce.
The company is divided into departments including Quality Management, Administration and Personnel, Integrated Procurement, Sales Management, Finance, Warehousing and Transportation, Information Management, and Marketing. Currently, the company operates 153 product varieties, with 16 varieties and 36 specifications having nationwide sales rights, and exports of approximately 10 or more pharmaceutical products. It has established offices in more than 20 provinces, cities, and autonomous regions across China, with 123 frontline sales personnel. The sales team is projected to expand to 150 people by 2023, and the extensive business channels and professional sales team provide a guarantee for annual sales growth of over 20%.